Medical Health & Life Science Research News

Rheumatoid arthritis - pipeline review with detailed analysis published by leading research firm

Medical Market Research

If you are want to study the Rheumatoid Arthritis or intend to be, then this guide will provide you comprehensive outlook. It’s vital for you to keep your knowledge up to date by keeping research and development (R&D) of major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide requirement according to your needs. 

- Advertising -

Rheumatoid Arthritis - Pipeline Review, H2 2017 is latest pipeline review released by HTF MI to provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis, complete with analysis by stage of development, drug target, root cause analysis ,mechanism of action (MoA), route of administration (RoA) and molecule type. 

Get Access to Sample PDF @: www.htfmarketreport.com/sample-rep…pipeline-review-1

Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. Rheumatoid arthritis may be a result of genetic and certain specific environmental factors.

- Advertising -

Women are much more susceptible to develop RA. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications and immunosuppressants.


Key Players included in the research study are 3SBio Inc, 4D Pharma PLC, AB Science SA, AbbVie Inc, Ablynx NV, ACEA Biosciences Inc, Aclaris Therapeutics Inc, Adello Biologics LLC, Allergan Plc, Alteogen Inc, Amarna Therapeutics BV, Amgen Inc, Amura Holdings Ltd, Applied Genetic Technologies Corp, Aptevo Therapeutics Inc, ARA Healthcare Pvt Ltd, arGentis Pharmaceuticals LLC, Arrien Pharmaceuticals LLC, Arthrogen BV, Asahi Kasei Pharma Corp, Astellas Pharma Inc, AstraZeneca Plc, Atlantic Bio Sci LLC, Aurigene Discovery Technologies Ltd, Axsome Therapeutics Inc, Axxam SpA, Baliopharm AG, BCN Peptides SA, Beijing Hanmi Pharmaceutical Co Ltd, Bio-Cancer Treatment International Ltd, Biocad, Biocon Ltd, BioLingus AG, BioLite Inc, Bionovis SA, Biozeus, Bird Rock Bio Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co, BTB Pharma AB, Cadila Healthcare Ltd, Can-Fite BioPharma Ltd, Cardax Inc, Carna Biosciences Inc, CASI Pharmaceuticals Inc, CEL-SCI Corp, Celgene Corp, Cell2B Advanced Therapeutics SA, Celltrion Inc, ChemoCentryx Inc, Chipscreen Biosciences Ltd, ChironWells GmbH, Chong Kun Dang Pharmaceutical Corp, CJ HealthCare Corp, Clevexel Pharma SAS, Coherus BioSciences Inc, Commence Bio Inc, Compugen Ltd, Crossject SA, CSL Ltd, Cyclacel Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Daiichi Sankyo Co Ltd, Diamyd Medical AB, Domainex Ltd, Dr. Reddy's Laboratories Ltd, Eisai Co Ltd, Eli Lilly and Co, Enceladus Pharmaceuticals BV, Endocyte Inc, Enzene Biosciences Ltd, F. Hoffmann-La Roche Ltd, Fountain Biopharma Inc, Fresenius SE & Co KGaA, Fujifilm Holdings Corporation, Galapagos NV, Gene Techno Science Co Ltd, Genentech Inc, Genfit SA, Genor BioPharma Co Ltd, Genosco Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Griffin Discoveries BV, Han Wha Pharma Co Ltd, Hanmi Pharmaceuticals Co Ltd, Hansa Medical AB, Hanwha Chemical Corp, Hetero Drugs Ltd, HitGen LTD, Huabo Biopharm Co Ltd, Hutchison MediPharma Ltd, Idogen AB, Immune Response BioPharma Inc, Immungenetics AG, ImmunoFrontier Inc, Immunwork Inc, Innate Pharma SA, Innovent Biologics Inc, Intas Pharmaceuticals Ltd, Istesso Ltd, Japan Tobacco Inc, JHL Biotech Inc, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, Jyant Technologies Inc, Kadmon Corp LLC, KAHR medical Ltd, Kang Stem Biotech Co Ltd, Karyopharm Therapeutics Inc, KPI Therapeutics Inc, Lead Pharma Holding BV, LG Chem Ltd, Lipocure Ltd, Livzon Pharmaceutical Group Inc, LSK BioPartners Inc, Lupin Ltd, Mabion SA, mAbxience SA, MacroGenics Inc, Maruho Co Ltd, Mebiopharm Co Ltd, MedAnnex Ltd, Medestea Research & Production SpA, MedImmune LLC, Merck & Co Inc, Merck KGaA, Mesoblast Ltd, Millennium Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corp, ModiQuest Group, Momenta Pharmaceuticals Inc, Morphotek Inc, Mycenax Biotech Inc, MYOS RENS Technology Inc, Myungmoon pharmaceutical Co Ltd, Navigen Inc, Nichi-Iko Pharmaceutical Co Ltd, Nissan Chemical Industries Ltd, Novartis AG, NovelMed Therapeutics Inc, NovImmune SA, Nuevolution AB, Numab Innovation AG, Omeros Corp, Oncobiologics Inc, Oncodesign SA, OncoImmune Inc, Ono Pharmaceutical Co Ltd, OSE Immunotherapeutics, Paras Biopharmaceuticals Finland Oy, Peptinov SAS, Pfenex Inc, Pfizer Inc, Pharmacyclics Inc, Pharmascience Inc, Pharmedartis GmbH, Philogen SpA, PlantForm Corp, PLx Pharma Inc, Principia Biopharma Inc, ProNoxis AB, Protab Ltd, Protalex Inc, Protalix BioTherapeutics Inc, Qilu Pharmaceutical Co Ltd, Qu Biologics Inc, R Pharm, ReceptoPharm Inc, RedHill Biopharma Ltd, Reliance Life Sciences Pvt Ltd, Resverlogix Corp, ReveraGen BioPharma Inc, Rhizen Pharmaceuticals SA, Ribomic Inc, Richter Gedeon Nyrt, Rottapharm Biotech Srl, Saje Pharma LLC, Sandoz International GmbH, Sareum Holdings Plc, SBI Biotech Co Ltd, Selecta Biosciences Inc, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, Shanghai Pharmaceutical Co Ltd, Shenzhen Salubris Pharmaceuticals Co Ltd, Synermore Biologics Co Ltd, Synovo GmbH, Takeda Pharmaceutical Co Ltd, Teijin Pharma Ltd, TheraMAB LLC, Tiziana Life Sciences Plc, Toleranzia AB, TTY Biopharm Company Ltd, Tumorend LLC, Twoxar Inc, TxCell SA, U.S. Stem Cell Inc, UCB SA, United BioPharma Inc, Vaccinex Inc, Valeant Pharmaceuticals International Inc, Vicore Pharma AB, viDA Therapeutics Inc, Xbrane Biopharma AB, Xencor Inc, XL-protein GmbH, Yungjin Pharm Co Ltd & Yuyu Pharma Inc. 

Make inquiry @ www.htfmarketreport.com/enquiry-be…pipeline-review-1 

The guide features dormant and discontinued projects and covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. 

Rheumatoid Arthritis pipeline guide helps in identifying and tracking emerging and major players moves in the market and their portfolios, enhances decision making capabilities and helps to create effective marketing strategies to gain competitive advantage in health care and pharmaceuticals industry. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The data and information sourced from the databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the latest key developments are captured on a real time basis. 

Access this research report @ www.htfmarketreport.com/buy-now?fo…amp;report=841030 

Extracts of Chapters from Rheumatoid Arthritis - Pipeline Review, H2 2017 
Chapter 1 , to describe the definition , overview and Therapeutics Development of Rheumatoid Arthritis. 
Chapter2, to analyze the pipeline overview of companies, Universities/Institutes and the product development under by companies, Universities/Institutes. 
Chapter3, Therapeutics Assessment of Rheumatoid Arthritis by Target, Mechanism of Action, Route of Administration and by Molecule Type. 
Chapter4, to display company profile involved in Therapeutics Development. 
Chapter5, Drug profile product description, Mechanism of action and R&D Progress of Rheumatoid Arthritis. 
Chapter 6,7, to describe Rheumatoid Arthritis Appendix, Methodology ,Coverage ,Secondary Research ,Primary Research ,Expert Panel Validation and Contact Us. 

Objective of this study 

- To provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis. 
- To reviews pipeline therapeutics for Rheumatoid Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 
- The pipeline guide features descriptive drug profiles for the pipeline products which comprises, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. 
- The pipeline guide reviews key companies involved in Rheumatoid Arthritis therapeutics and enlists all their major and minor projects. 
- The pipeline guide evaluates Rheumatoid Arthritis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. 
- The guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis 

Reasons to access

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. 
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. 
- Find and recognize significant and varied types of therapeutics under development for Rheumatoid Arthritis. 
- Classify potential new clients or partners in the target demographic. 
- Develop tactical initiatives by understanding the focus areas of leading companies. 
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. 
- Formulate corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Indication therapeutics. 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. 

Read Detailed Index of full Research Study at @ www.htfmarketreport.com/reports/84…pipeline-review-1 

News From

HTF Market Intelligence ConsultingHTF Market Intelligence...
Category: Market Research Publishers and RetailersCompany about: HTF Market Report is wholly owned brand of HTF market Intelligence Consulting Private Limited which provides next-generation service for organizations with a deep focus on market intelligence, data analytics, and social intelligence, all uniquely delivered under one roof by skilled professionals. By combining and analyzing acquire lucid and most relevant data which would help in better decision-making. We provide your requirements with speed and cost benefit across the world, we are able to achi ...
This email address is being protected from spambots. You need JavaScript enabled to view it.